Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
- 1 April 2011
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (10), 1232-1235
- https://doi.org/10.1200/jco.2010.33.2684
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJournal of Clinical Oncology, 2010
- SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancerAnnals of Oncology, 2010
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluationEuropean Journal Of Cancer, 2009
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005